Research ExplorerPublications[Active surveillance for prostate cancer]

[Active surveillance for prostate cancer]

Standard

[Active surveillance for prostate cancer]. / Graefen, Markus; Ahyai, Sascha; Heuer, Roman; Salomon, Georg; Schlomm, Thorsten; Isbarn, Hendrik; Budäus, Lars; Heinzer, Hans; Huland, Hartwig.

In: UROLOGE, Vol. 47, No. 3, 3, 2008, p. 261-269.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Graefen, M, Ahyai, S, Heuer, R, Salomon, G, Schlomm, T, Isbarn, H, Budäus, L, Heinzer, H & Huland, H 2008, '[Active surveillance for prostate cancer]', UROLOGE, vol. 47, no. 3, 3, pp. 261-269. <http://www.ncbi.nlm.nih.gov/pubmed/18273597?dopt=Citation>

APA

Graefen, M., Ahyai, S., Heuer, R., Salomon, G., Schlomm, T., Isbarn, H., Budäus, L., Heinzer, H., & Huland, H. (2008). [Active surveillance for prostate cancer]. UROLOGE, 47(3), 261-269. [3]. http://www.ncbi.nlm.nih.gov/pubmed/18273597?dopt=Citation

Vancouver

Graefen M, Ahyai S, Heuer R, Salomon G, Schlomm T, Isbarn H et al. [Active surveillance for prostate cancer]. UROLOGE. 2008;47(3):261-269. 3.

Bibtex

@article{cce3955a04864c839d515ec10fe22547,
title = "[Active surveillance for prostate cancer]",
abstract = "Active surveillance is a valuable treatment option in patients with newly diagnosed low-risk prostate cancer. Studies considering a watchful waiting approach showed favourable cancer-specific survival rates in such patients and it is assumed that patients benefit from a definitive therapy if life expectancy exceeds 10-15 years. Therefore active surveillance is especially valuable in older men and in patients with an elevated comorbidity profile.Precise identification of histologically and clinically insignificant prostate cancers is still not possible today. Active surveillance includes regular PSA measurements combined with follow-up biopsies; however, no standardized protocol exists so far. Histological progression in the follow-up biopsy and PSA elevation are the most important criteria for initiating definitive therapy.Today only a minority of low-risk patients join an active surveillance protocol and a substantial proportion of these men leave such a protocol early without evidence of progression. The psychological burden of living with an untreated cancer seems to be responsible for this. Active surveillance has the potential to lead to undertreatment as there is some evidence that prolonged treatment delay might adversely affect outcome of definitive therapy.",
author = "Markus Graefen and Sascha Ahyai and Roman Heuer and Georg Salomon and Thorsten Schlomm and Hendrik Isbarn and Lars Bud{\"a}us and Hans Heinzer and Hartwig Huland",
year = "2008",
language = "Deutsch",
volume = "47",
pages = "261--269",
journal = "UROLOGE",
issn = "0340-2592",
publisher = "Springer",
number = "3",

}

RIS

TY - JOUR

T1 - [Active surveillance for prostate cancer]

AU - Graefen, Markus

AU - Ahyai, Sascha

AU - Heuer, Roman

AU - Salomon, Georg

AU - Schlomm, Thorsten

AU - Isbarn, Hendrik

AU - Budäus, Lars

AU - Heinzer, Hans

AU - Huland, Hartwig

PY - 2008

Y1 - 2008

N2 - Active surveillance is a valuable treatment option in patients with newly diagnosed low-risk prostate cancer. Studies considering a watchful waiting approach showed favourable cancer-specific survival rates in such patients and it is assumed that patients benefit from a definitive therapy if life expectancy exceeds 10-15 years. Therefore active surveillance is especially valuable in older men and in patients with an elevated comorbidity profile.Precise identification of histologically and clinically insignificant prostate cancers is still not possible today. Active surveillance includes regular PSA measurements combined with follow-up biopsies; however, no standardized protocol exists so far. Histological progression in the follow-up biopsy and PSA elevation are the most important criteria for initiating definitive therapy.Today only a minority of low-risk patients join an active surveillance protocol and a substantial proportion of these men leave such a protocol early without evidence of progression. The psychological burden of living with an untreated cancer seems to be responsible for this. Active surveillance has the potential to lead to undertreatment as there is some evidence that prolonged treatment delay might adversely affect outcome of definitive therapy.

AB - Active surveillance is a valuable treatment option in patients with newly diagnosed low-risk prostate cancer. Studies considering a watchful waiting approach showed favourable cancer-specific survival rates in such patients and it is assumed that patients benefit from a definitive therapy if life expectancy exceeds 10-15 years. Therefore active surveillance is especially valuable in older men and in patients with an elevated comorbidity profile.Precise identification of histologically and clinically insignificant prostate cancers is still not possible today. Active surveillance includes regular PSA measurements combined with follow-up biopsies; however, no standardized protocol exists so far. Histological progression in the follow-up biopsy and PSA elevation are the most important criteria for initiating definitive therapy.Today only a minority of low-risk patients join an active surveillance protocol and a substantial proportion of these men leave such a protocol early without evidence of progression. The psychological burden of living with an untreated cancer seems to be responsible for this. Active surveillance has the potential to lead to undertreatment as there is some evidence that prolonged treatment delay might adversely affect outcome of definitive therapy.

M3 - SCORING: Zeitschriftenaufsatz

VL - 47

SP - 261

EP - 269

JO - UROLOGE

JF - UROLOGE

SN - 0340-2592

IS - 3

M1 - 3

ER -